(Q46614689)

23 December 2017

title

Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10). (English)

1 reference

23 December 2017

adaptive radiation therapy

main subject

phase II clinical trial

0 references

phase I clinical trial

0 references

0 references

1 reference

Michael Perrotti

1

1 reference

23 December 2017

Todd Doyle

2

1 reference

23 December 2017

Parvesh Kumar

3

1 reference

23 December 2017

Daryl McLeod

4

1 reference

23 December 2017

William Badger

5

1 reference

23 December 2017

Susan Prater

6

1 reference

23 December 2017

Michael Moran

7

1 reference

23 December 2017

Stuart Rosenberg

8

1 reference

23 December 2017

Cora Bonatsos

9

1 reference

23 December 2017

Carrie Kreitner

10

1 reference

23 December 2017

Ralf Kiehl

11

1 reference

23 December 2017

Theodore Chang

12

1 reference

23 December 2017

Michael Kolodziej

13

1 reference

23 December 2017

publication date

8 January 2008

1 reference

23 December 2017

published in

Urologic Oncology

1 reference

23 December 2017

volume

26

1 reference

23 December 2017

issue

3

1 reference

23 December 2017

page(s)

276-280

1 reference

23 December 2017

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.04.003

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.04.003

Management of locally advanced prostate cancer: past, present, future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.04.003

Evolving role of surgery, radiation, hormone therapy, and chemotherapy in high-risk locally advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.04.003

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.04.003

HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.04.003

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.04.003

Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.04.003

Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.04.003

Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.04.003

Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.04.003

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.04.003

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.04.003

Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.04.003

Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: feasibility and preliminary results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.04.003

Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.04.003

Phase I study of docetaxel with concomitant thoracic radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.04.003

Practical aspects of weekly docetaxel administration schedules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.04.003

Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.04.003

Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.04.003

Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.04.003

10.1016/J.UROLONC.2007.04.003

7 January 2021

Identifiers

DOI

1 reference

23 December 2017

release_mdzhkxfjkjddtptunhahgste6q

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mdzhkxfjkjddtptunhahgste6q

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

23 December 2017